Treatment of patients with von Willebrand disease

References

• RodeghieroFCastamanGDiniEEpidemiological investigation of the prevalence of von Willebrand’s diseaseBlood19876924544593492222
   PubMed Web of Science ®Google Scholar
• ManuscoDJTuleyEAWestfieldLAStructure of the gene for human von Willebrand FactorJ Biol Chem1989264331951919527
   Web of Science ®Google Scholar
• SadlerJEA revised classification of von Willebrand diseaseThromb Haemost19947145205258052974
   PubMed Web of Science ®Google Scholar
• SadlerJEBuddeUEikenboomJCUpdate on the pathophysiology and classification of von Willebrand diseaseJ Thromb Haemost20064102103211416889557
   PubMed Web of Science ®Google Scholar
• KaufmanJEOkscheAWollheimCBGuntherGRosenthalWVischerUMVasopressin induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMPJ Clin Invest2000106110711610880054
   PubMed Web of Science ®Google Scholar
• MannuciPMAlberyMNilssonIMRobertsonBMechanism of plasminogen activation and factor VIII increase after vasoactive drugsBr J Haematol197530181931191576
   PubMed Web of Science ®Google Scholar
• MannuciPMCancianiMTRotaLDonovanBSResponse of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand diseaseBr J Haematol19814722832936781527
   PubMed Web of Science ®Google Scholar
• RodegheroFCastamanGMannuciPMProspective multicentre study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate haemophilia AThromb Haemost19967656926968950775
   PubMed Web of Science ®Google Scholar
• SmithTJGillJCAmbrusoDRHathawayWEHyponatraemia and seizures in young children given DDAVPAm J Hematol19893131992022500851
   PubMed Web of Science ®Google Scholar
• MannucciPMDesmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 yearsBlood1997907251525219326215
   PubMed Web of Science ®Google Scholar
• FedericiABMazurierCBerntorpEBiologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European studyBlood200410362032203814630825
   PubMed Web of Science ®Google Scholar
• CastamanGLethagenSFedericiABResponse to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (vWD): results from the European Study MCMDM-1vWDBlood200811173531353918230755
   PubMed Web of Science ®Google Scholar
• BrownSAEldridgeACollinsPWBowenDJIncreased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process?J Thromb Haemost2003181714171712911582
   PubMed Web of Science ®Google Scholar
• CasanatoAPontaraESartorelloFReduced von Willebrand factor survival in type Vincenza von Willebrand diseaseBlood200299118018411756169
   PubMed Web of Science ®Google Scholar
• MichielsJJvan de VeldeAvan VlietHHvan der PlankenMSchroyensWBernemanZResponse of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implicationsSemin Thromb Hemost200228211113211992235
   PubMed Web of Science ®Google Scholar
• GralnickHRWilliamsSBMcKeownLPDDAVP in type IIa von Willebrand’s diseaseBlood19866724654683080040
   PubMed Web of Science ®Google Scholar
• CasonatoAPontaraEDannhaeuserDRe-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand’s diseaseBlood Coagul Fibrinolysis1994569599647893933
   PubMed Web of Science ®Google Scholar
• FowlerWEBerkowitzLRRobertsHRDDAVP for type IIB von Willebrand diseaseBlood1989745185918602790211
   PubMed Web of Science ®Google Scholar
• MazurierCGaucherCJorieuxSGoudemandMBiological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Collaborative GroupBr J Haematol19948848498547819109
   PubMed Web of Science ®Google Scholar
• MannucciPMBettegaDCattancoMPatterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP)Br J Haematol199282187931419807
   PubMed Web of Science ®Google Scholar
• ByrnesJJLacardaAMoakeJLThrombosis following desmopressin for uremic bleedingAm J Hematol198828163653259400
   PubMed Web of Science ®Google Scholar
• BondLBevanDMyocardial Infarction in a patient with haemophilia treated with DDAVPN Eng J Med19883182121
   Web of Science ®Google Scholar
• MannucciPMTreatment of von Willebrand’s DiseaseN Engl J Med2004351768369415306670
   PubMed Web of Science ®Google Scholar
• MazurierCComposition, quality control and labeling of plasma-derived products for the treatment of von Willebrand diseaseSemin Thromb Hemost200632552953616862527
   PubMed Web of Science ®Google Scholar
• HewittPELlewelynCAMacKenzieJWillRGCreutzfeld-Jacob Disease and blood transfusion : results of the UK Transfusion Medicine Epidemiological Review StudyVox Sang200691322123016958834
   PubMed Web of Science ®Google Scholar
• Health Protection Report202200937
   Google Scholar
• HubbardARVon Willebrand factor standards for plasma and concentrate testingSemin Thromb Hemost200632552252816862526
   PubMed Web of Science ®Google Scholar
• DobrkovskaAKrzenskUChediakJRPharmacokinetics, efficacy and safety of Humate-P in von Willebrand diseaseHaemophilia19984Suppl 3333910028316
   PubMed Web of Science ®Google Scholar
• FavaloroEJLloydJRoswellJComparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised crossover, multi-centre studyThromb Haemost200797692293017549293
   PubMed Web of Science ®Google Scholar
• GoudemandJScharrerIBerntorpEPharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methodsJ Thromb Haemost20053102219222716194199
   PubMed Web of Science ®Google Scholar
• LubetskyAMartinowitzULuboshitzJEfficacy and safety of a factor VIII- von Willebrand concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experienceHaemophilia20028562262812199669
   PubMed Web of Science ®Google Scholar
• MannucciPMChediakJHannaWfor Alphanate Study GroupTreatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter studyBlood200299245045611781224
   PubMed Web of Science ®Google Scholar
• FedericiABBaudoFCaraccioloCClinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical studyHaemophilia20028676176712410644
   PubMed Web of Science ®Google Scholar
• BelloIFYusteVJMolinaMQNavarroFHFanhdi, efficacy and safety in von Willebrand’s disease: prospective international study resultsHaemophilia200713Suppl 5253218078394
   PubMed Web of Science ®Google Scholar
• PasiKJCollinsPWKeelingDMManagement of con Willebrand disease: guidelines from the UK Haemophilia Centre Doctors’ OrganizationHaemophilia200410321823115086319
   PubMed Web of Science ®Google Scholar
• CollinsPWTreatment of von Willebrand disease: therapeutic concentratesLeeCABerntorpEEHootsWKTextbook of HemophiliaOxfordBlackwell Publishing2010322
   Google Scholar
• LethagenSKyrlePACastamanGfor Haemate P Surgical Study GroupVon Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicentre trial in elective surgeryJ Thromb Haemost2007571420143017439628
   PubMed Web of Science ®Google Scholar
• MakrisMColvinBGuptaVShieldsMLSmithMPVenous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s diseaseThromb Haemostat2002883387388
   Web of Science ®Google Scholar
• MannucciPMVenous thromboembolism in von Willebrand diseaseThromb Haemost200288337837912353063
   PubMed Web of Science ®Google Scholar
• KyrlePAMinarEHirschlMHigh plasma levels of factor VIII and the risk of recurrent venous thromboembolismN Engl J Med2000343745746210950667
   PubMed Web of Science ®Google Scholar
• MannuciPMFranchiniMCastamanGfor Italian Association of Hemophilia CentersEvidence-based recommendations on the treatment of von Willebrand disease in ItalyBlood Transfus20097211712619503633
   PubMed Web of Science ®Google Scholar
• FedericiABCastamanGMannucciPMfor Italian Association of Hemophilia Centres (AICE)Evidence-based recommendations on the treatment of von Willebrand disease in ItalyHaemophilia20028560762112199668
   PubMed Web of Science ®Google Scholar
• LillicrapDPoonMCWalkerIfor Association of Hemophilia Clinic Directors of CanadaEfficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand diseaseJ Thromb Haemost2002872224230
   Google Scholar
• MannucciHemostatic DrugsN Engl J Med199833942452539673304
   PubMed Web of Science ®Google Scholar
• LingardhGAndersonLClot retention in the kidney as a probable cause of anuria during treatment of haematuria with epilson-aminocapric acidActa Med Scand196618044694735924536
   PubMedGoogle Scholar
• ZwischenbergerJBBrunstonRLJrSwannJRContiVRComparison of two topical collagen-based hemostatic sponges during cardiothoracic proceduresJ Invest Surg199912210110610327079
   PubMed Web of Science ®Google Scholar
• CastilloRMonteagudoJEscolarGHemostatic effect of normal platelet transfusion in severe von Willebrand disease patientsBlood1991779190119051902120
   PubMed Web of Science ®Google Scholar
• GreerIALoweGDWalkerJJForbesCDHaemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathiesBr J Obstet Gynaecol19919899099181911610
   PubMedGoogle Scholar
• NicholsWLHultinMBJamesAHVon Willebrand disease (vWD): evidence-based diagnosis and management guidelines, the National Heart, Lung and Blood institute (NHLBI) Expert Panel report (USA)Haemophilia200814217123218315614
   PubMed Web of Science ®Google Scholar
• ChuongCJBrennerPFManagement of abnormal uterine bleedingAm J Obstet Gynecol19961753 Pt 27877928828563
   PubMed Web of Science ®Google Scholar
• FosterPAThe reproductive health of women with von Willebrand disease unresponsive to DDAVP : results of an international survery on behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standarization committee of the ISTHThromb Haemost19957427847908585022
   PubMed Web of Science ®Google Scholar
• KiratavaADrewsCLallyCDilleyAEvattBMedical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case- control studyHaemophilia20039329229712694520
   PubMed Web of Science ®Google Scholar
• LahteenmakiPHaukkamaaMPuolakkaJOpen randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomyBMJ19983167138112211269552948
   PubMed Web of Science ®Google Scholar
• PettitiDBClinical practice: combination estrogen–progestin oral contraceptivesN Engl J Med2003349151443145014534338
   PubMed Web of Science ®Google Scholar
• RosendaalFRHelmerhorstFMVandenbrouckeJPFemale hormones and thrombosisArterioscler Thromb Vasc Biol200222220121011834517
   PubMed Web of Science ®Google Scholar
• BellerFKEbertCEffects of oral contraceptives on blood coagulation: a reviewObstet Gynecol Surv19854074254363895067
   PubMedGoogle Scholar
• KadirRAEconomidesDLSabinCAOwensDLeeCAVariations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptiveThromb Haemost19998251456146110595638
   PubMed Web of Science ®Google Scholar
• MiddeldorpSMeijersJVvan den EndeAEEffects on coagulation of levonorgesterel- and desogesterel-containing low dose oral contraceptives: a cross-over studyThromb Haemost20001844810928461
   PubMed Web of Science ®Google Scholar
• DavisAGodwinALippmanJOlsonWKafrissenMTriphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleedingObstet Gynecol200096691392011084177
   PubMed Web of Science ®Google Scholar
• SharpHTAssessment of new technology in the treatment of idiopathic menorrhagia and uterine leiomyomataObstet Gynecol20061084990100317012464
   PubMed Web of Science ®Google Scholar
• SiePCaronCAzamJGoudemandJReassessment of von Willebrand factor (vWF), vWF propetide, factor VIII. C and plasminogen activator inhibitors 1 and 2 during normal pregnancyBr J Haematol2003121689790312786801
   PubMed Web of Science ®Google Scholar
• KadirRALeeCASabinCAPollardDEconomidesDLPregnancy in women with von Willebrand’s disease or factor XI deficiencyBr J Obstet Gynaecol199810533143219532993
   PubMedGoogle Scholar
• RamsahoyeBHDaviesSVDasaniHRearsonJFObstetric management in von Willebrands disease: a report of 24 pregnancies and review of the literatureHaemophilia199512140144
   Web of Science ®Google Scholar
• AlperinJBEstrogens and surgery in women with von Willebrand’s diseaseAm J Med19827333673716981997
   PubMed Web of Science ®Google Scholar
• ContiMMariDContiEMuggiascaMLMannucciPMPregnancy in women with different types of von Willebrand diseaseObstet Gynecol19866822822853090493
   PubMed Web of Science ®Google Scholar
• ChediakJRAlbanGMMaxeyBvon Willebrands disease and pregnancy: management during delivery and outcome of offspringAm J Obstet Gynaecol19861553618624
   Web of Science ®Google Scholar
• CasonatoASartoriMTBertomoroAFedeTVasoinFGirolamiAPregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrands diseaseBlood Coagul Fibrinolysis19912133401772996
   PubMed Web of Science ®Google Scholar
• KouidesPAObstetric and gynaecological aspects of von Willebrand diseaseBest Pract Res Clin Haematol200114228129911686100
   PubMed Web of Science ®Google Scholar
• RayJGDDAVP use during pregnancy: an analysis of its safety for mother and childObstet Gynecol Surv19985374504559662731
   PubMedGoogle Scholar
• MannucciUse of desmopressin (DDAVP) during early pregnancy in factor VIII deficient womenBlood20051058338215802549
   PubMed Web of Science ®Google Scholar
• DahlmanTHellgrenMBlombackMChanges in blood coagulation and fibrinolysis in the normal puerperiumGynecol Obstet Invest198520137443930349
   PubMed Web of Science ®Google Scholar
• Borel-DerlonAFedericiABRoussel-RobertVTreatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patientsJ Thromb Haemost2007561115112417403090
   PubMed Web of Science ®Google Scholar
• LakMPeyvandiFMannucciPClinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand diseaseHaemophilia2000111412361239
   Google Scholar
• FedericiABClinical diagnosis of von Willebrand diseaseHaemophilia200410Suppl 416917615479393
   PubMed Web of Science ®Google Scholar
• BerntorpEPetriniPLong-term prophylaxis in von Willebrand diseaseBlood Coagul Fibrinolysis200516Suppl 1S23S2615849523
   PubMed Web of Science ®Google Scholar
• BerntorpEAbshireTfor von Willebrand Disease Prophylaxis Network Steering CommitteeThe von Willebrand disease prophylaxis network: exploring a treatment conceptJ Throm Haemost2006425112512
   Web of Science ®Google Scholar
• FedericiABBarillariGZanonEEfficacy and safety of highly purified doubly virus inactivated vWF/FVIII concentrates in the management of inherited von Willebrand disease: results from the retrospective Italian study on 120 casesPoster presented: 28th World Federation of Hematology CongressIstanbul, Turkey1–5 June 2008 abstract 713.
   Google Scholar
• ClinicalTrials.gov (homepage on the Internet). Pharmacokinetic, Safety and Tolerability Study of Recombinant von Willebrand factor/Recombinant Factor VIII Complex in Type 3 von Willebrand Disease. [Updated February 23, 2011]. Available from http://clinicaltrials.gov/ct2/show/NCT00816660/accessed February 23, 2011.
   Google Scholar